Loss of Pulse Detection

The Fitbit Loss of Pulse Detection software is a mobile application designed to detect potential loss of pulse events in users via compatible wrist-worn devices and provide timely alerts, including prompting emergency services. It operates by analyzing pulse data through proprietary algorithms, validated by comprehensive performance, bench, software, and human factors studies, as well as real-world and clinical validation, demonstrating high sensitivity and specificity in event detection.

A new software-only mobile application, Loss of Pulse Detection, developed by Fitbit, has been determined to be substantially equivalent to a legally marketed device. This software is intended for over-the-counter use with compatible wrist-worn products to analyze pulse data and identify potential loss of pulse events. It provides audio, visual, and haptic alerts to the user, and if the user remains unresponsive, it can prompt a call to emergency services through a connected device. This application is not meant to replace traditional diagnostic or treatment methods and is not intended for use by individuals under 22 years of age or those with pre-existing high-risk cardiac conditions. The determination was made after a review of the device, which included performance data from algorithm development, bench testing, software testing, and human factors studies. Real-world evidence and clinical validation studies were also conducted, demonstrating the software's ability to detect loss of pulse events with reported sensitivity and specificity, and no adverse events directly related to the software were reported. The manufacturer is reminded to adhere to ongoing regulatory requirements, including device registration, listing, good manufacturing practices, appropriate labeling, medical device reporting, and compliance with Unique Device Identification (UDI) regulations.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What are the specific algorithms and physiological parameters utilized by the Loss of Pulse Detection software to identify a "loss of pulse event" and differentiate it from other non-event scenarios like sensor dislodgement?; Given the "over-the-counter" nature, how were the human factors studies designed to ensure proper use and interpretation of alerts by a general user population, especially concerning potential false positives or negatives?; What specific clinical scenarios and patient populations were included in the real-world evidence and clinical validation studies, and how do the reported sensitivity and specificity metrics translate to actual clinical utility and potential impact on patient outcomes?; What are the limitations of the "compatible wrist-worn products" in terms of pulse data accuracy, and how does the software account for potential artifacts or variations in data quality across different compatible devices?; Since it's not intended for those with "pre-existing high-risk cardiac conditions," what specific mechanisms or labeling strategies are in place to prevent misuse or misinterpretation by such individuals who might benefit from or mistakenly rely on this technology?